Healthtech Startups

Ellement produces personalized prenatal supplements customized monthly to individual nutritional needs from preconception through postpartum. The products are formulated with 30+ key nutrients, free from common allergens and fillers, and manufactured in small batches in the USA.

1 investor

Flow Space provides science-based content and educational resources focused on women's health topics, addressing historical gaps in health research and information for female audiences.

1 investor

Hopscotch Primary Care provides primary care services for adults with Medicare or Medicare/Medicaid, with a focus on rural communities in North Carolina. The company operates clinics delivering proactive, value-based care through multidisciplinary teams with longer appointment times and same-day access.

1 investor

River Health offers employer-sponsored healthcare benefits including virtual primary care visits, therapy, urgent care clinic access, prescriptions, and specialty care at no cost to employees. The platform serves employees at participating Fortune 500 companies and small businesses through a mobile app and network of partner clinics.

1 investor

Ro offers dermatology and hair care through telemedicine, connecting patients with US-licensed healthcare professionals for online visits, prescription treatments, compounded medications, and over-the-counter products delivered to the home. It serves consumers seeking hair and skin treatments for concerns such as hair loss, acne, aging, and eyelash growth.

1 investor

Sunrise develops a wireless single-use sensor and companion iOS/Android app that records the respiratory signal at its source to detect sleep apnea at home in one night. It provides clinical reports that patients can share with their doctor or the company's network of partner sleep specialists for diagnosis and tailored treatment.

1 investor

Platform enabling carriers to launch configurable dynamic copay health plans.

1 investor

Predictive Oncology (POAI) operates an AI/ML platform powered by a biobank of over 150,000 tumor samples across 137 cancer types to predict tumor-drug response for oncology drug discovery. It serves pharmaceutical drug developers, offering drug-response predictions, drug repurposing, and pre-clinical tumor heterogeneity modeling.

1 investor

Help at Home provides in-home care services, matching trained caregivers with clients to deliver personalized support focused on maintaining health and independence. The company emphasizes long-term caregiver-client relationships, caregiver training, and preventive care to reduce hospitalizations and improve quality of life for elderly and vulnerable adults.

1 investor

Helppad develops a sheet-type sensor system that detects urine and feces using smell, humidity, and temperature data to notify caregivers of optimal diaper change timing in elderly care facilities. The product reduces unnecessary diaper changes, caregiver workload, and sleep disruption for care recipients.

1 investor

Helpper operates a Flemish online platform that connects people needing help at home with screened local helpers for practical assistance, companionship, and care support. It serves budget holders (PVB/PAB), informal caregivers, seniors, and care professionals across Flanders and Brussels, and handles the relevant VAPH documentation.

1 investor

Helpr provides employer-sponsored backup care benefits, connecting employees and their families with vetted care providers globally through patented software. It offers a use-based, subsidized model that lets workers choose and pay providers in their local currency, serving enterprises and their employees from hourly staff to executives.

1 investor

Helsinn is a global pharmaceutical company that develops and distributes supportive care medications for patients with cancer and chronic diseases. The company operates through a combination of direct sales in the United States and commercial partnerships internationally.

1 investor

Hemeo develops AI-based clinical decision support software that consolidates data from multiple sources to predict coagulation risks and personalize the prevention and treatment of bleeding and thrombosis. It is aimed at doctors managing coagulation complications, with the goal of reducing blood transfusions and improving patient survival.

1 investor

Hemerion develops photonic drug-device combination therapies for treating glioblastomas and other brain tumors in clinical settings. The company combines photosensitizing drugs with innovative photonic systems designed to integrate into surgical workflows and selectively destroy tumor cells.

1 investor

HEMI provides a proprietary clinical AI platform serving hospitals, clinicians, and patients across Southeast Asia, with particular strength in Malaysia. The company owns its underlying AI models and offers medicolegal protection as a core architectural feature, differentiating it from licensed-model competitors.

1 investor

Newton is an AI front-office agent for dental practices that handles calls, scheduling, insurance verification, and payment collection across multiple locations. It provides dental groups and DSOs with centralized visibility into performance metrics and operational efficiency through a unified system integrated with practice management software.

1 investor

Hemo Group develops interventional medical devices for treating neuro-vascular diseases, including ischemic stroke, hemorrhagic stroke, and neuro access, with products such as the Afentta intracranial thrombectomy device. The company markets its devices across Europe, Asia, and the Middle East, with R&D conducted in the US.

1 investor

Abbott Global Point of Care provides portable diagnostic analyzers and testing systems used at the point of care by healthcare professionals, enabling on-site blood chemistry, lipid, and other tests with results that can upload directly to electronic medical records. Its products serve clinical and near-patient testing settings in the in-vitro diagnostics category.

1 investor

Hemostemix is a clinical-stage regenerative medicine company developing ACP-01, an investigational autologous (patient-derived) stem cell therapy for vascular and ischemic conditions such as critical limb ischemia, peripheral arterial disease, ischemic cardiomyopathy, and heart failure. The company runs Phase I and Phase II clinical programs and is publicly traded (TSXV: HEM | OTCQB: HMTXF).

1 investor

Henlez is an early-stage biotech company working in the dermatology space.

1 investor

HepQuant develops noninvasive, blood-based quantitative tests that measure liver cell function and blood flow to assess liver health and disease severity. The tests are used by healthcare providers to manage patients with advanced liver disease and by drug developers in clinical trials.

1 investor

1 investor

Hera Women's Health partners with independent women's health providers to deliver clinical and operational support, modernizing practice operations while preserving physician independence and community relationships. The organization aims to improve healthcare delivery for women by removing administrative barriers and enabling providers to focus on patient care.

1 investor